EFPIA - NEWSLETTER

Trouble reading this email? View it in your browser


		EFPIA Newsletter 24 April 2025

Rare Disease Moonshot’s contribution to the Call for Evidence on the EU Life Science Strategy

The Rare Disease Moonshot has responded to the European Commission’s call for evidence on the forthcoming EU Life Science Strategy. Rooted in the experiences of people living with rare diseases, the submission emphasises the need for a more inclusive, innovation-driven ecosystem that bridges research and care. It calls for bold, coordinated action to ensure that no patient is left behind.

Read the full contribution here.

New publications

White Paper on pharmaceutical packaging
24 April 2025

Building a healthier and more environmentally sustainable future Read more

Strengthening Europe’s clinical trial environment
15 April 2025

European clinical trials are currently hampered by a slow and fragmented research ecosystem. Read more

Recent publications

IHE Cancer Comparator Report 2025
19 March 2025

Cancer survival rates improve across Europe, but disparities between countries remain Read more

Events

International conference on protein stability – The gap between industry and administration...
13 May 2025 (Södertälje Science Park, Sweden)

The objective of this symposium/conference is to create an arena for discussions on the recent research and industrial... Read more

JLABS | Paths to the patient: Business models for drug discovery and development
03 June 2025 (Utrecht, The Netherlands)

How do you choose the right path to bring your drug discovery to patients? Join this JLABS program to discover the pros... Read more

Join the IHI webinar: Impact on Cancer

On 19 May 2025, join the Innovative Health Initiative webinar to explore how IHI and IMI projects are making an impact in cancer research and care.

Register for the webinar here.

What we are reading

EU holds firm on pharma reform proposal despite industry pressure
On 23 April 2025 (Euronews)

The European Commission has no plans to withdraw or revise its proposed overhaul of EU pharmaceutical rules, despite... Read more

Europe’s pharmaceutical industry wants more clarity on ICH’s modeling guideline
On 21 April 2025 (Regulatory Focus)

Pharmaceutical industry groups say that more information and examples are necessary to effectively use various modeling... Read more

International IP Index warns EU efforts to weaken pharma IP could cause investment to migrate...
On 16 April 2025 (IP Watch Dog)

The U.S. Chamber of Commerce’s Global Innovation Policy Center (GIPC) published the 2025 International... Read more

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
E-mail:Communications@efpia.eu